The Narcolepsy Drug That Used to Be a Party Drug, and What That History Should and Shouldn’t Change
The most effective drug for her cataplexy is, chemically, the same compound once better known as a club drug and a date-rape agent. The disagreement isn’t about efficacy — it’s about how much of that history belongs in the conversation, and how much of it is just baggage.
A.V., a 26-year-old woman, has worked as a veterinary technician since finishing her certification five years ago, a job she chose after growing up on a small farm and genuinely loves, despite its physical demands — restraining large, sometimes frightened animals, standing for most of a twelve-hour shift. She was diagnosed with narcolepsy type 1 two years ago after a pattern of sudden, brief muscle weakness that she initially found almost funny before it started scaring her: her knees buckling when she laughed hard at a friend’s joke, her jaw going briefly slack mid-sentence when startled by a dog barking unexpectedly behind her, all alongside significant daytime sleepiness that had been building for at least a year before that.
Her episodes have become more frequent over the past six months, several a week now rather than the occasional event she started with, despite modafinil, which has genuinely helped her daytime sleepiness — she stays alert through her shifts now in a way she couldn’t before — but does nothing for the cataplexy itself, and her clinic’s safety officer has already raised concerns about her working directly around large animals during an active episode. She has no history of substance use of any kind and no other medical conditions.
Her sleep specialist raised sodium oxybate as the most effective treatment specifically for cataplexy, and she recognized the name immediately — not from any medical context, but from news coverage and a mandatory college health seminar years ago warning students about GHB as a drug of abuse and a facilitator of assault. She asked, directly and without embarrassment, whether this was “the same thing,” and whether she should be worried about what it actually means, practically and socially, to be prescribed it.
In clinic, after she asked the question directly
The honest answer to her question is yes — sodium oxybate is the sodium salt of GHB, the same molecule, and that’s worth saying plainly rather than deflecting. What’s also true is that it remains the most effective medication we have for cataplexy specifically, through GABA-B receptor agonism that consolidates fragmented nighttime sleep architecture in narcolepsy — its efficacy for exactly her symptom isn’t in question. It is not the only approved option: pitolisant has carried an FDA cataplexy indication in adults since October 2020. But in the HARMONY CTP trial its cataplexy reduction was roughly 75% from baseline versus 38% on placebo, which is a real effect and a more modest one than oxybate delivers in a patient whose attacks are already escalating.
It carries a REMS program — mandatory prescriber and pharmacy certification, patient education, and a boxed warning for CNS depression and abuse potential — specifically because of that history, and that structure exists as a real, working safeguard, not window dressing.
I want to separate the molecule’s history from her actual risk, because those are being run together more than they should be. GHB’s reputation as a club drug and a facilitator of drug-assisted assault reflects how it has been misused by people without a narcolepsy diagnosis, at uncontrolled recreational doses, often combined with alcohol — none of which describes what’s being proposed here: a precisely dosed, REMS-monitored prescription for a patient with no substance use history and a clear, distinct medical indication.
She’s not wrong to ask the question — the chemistry really is the same — but the risk calculus for a prescribed, monitored patient with narcolepsy and no misuse history bears little resemblance to the recreational-use risk her college seminar was actually warning about, and I think it’s important she hears that distinction clearly, not just the shared name.
Where I do want to push back is on how the choice was framed to her. You said oxybate’s efficacy for her symptom isn’t in question, and I agree — but pitolisant is approved for cataplexy too and isn’t a controlled substance at all, which is precisely the axis she raised the concern on. If her worry is “am I being handed the date-rape drug,” the honest answer includes that there is an approved option with no scheduling status and no REMS, that it is less effective for cataplexy than oxybate, and that we are recommending the more effective drug knowing that trade-off. Presenting oxybate as the only door available would settle her anxiety by leaving something out, and she is the kind of patient who will find it later and wonder what else we simplified.
The one place I’d add nuance is on the practical burden, separate from the history question entirely. Sodium oxybate requires two nightly doses roughly 2.5–4 hours apart, meaning she has to wake herself for a second dose — a genuinely disruptive regimen that has nothing to do with the drug’s reputation and everything to do with its short half-life.
For an active, physically demanding job with early shifts, that’s a real adherence consideration worth naming alongside the history conversation, not instead of it — the newer once-nightly extended-release formulation exists specifically because this burden is real, and might be worth discussing with her directly as an alternative.
Agreed: sodium oxybate started under REMS, with modafinil continued, and an explicit, honest conversation with A.V. about the GHB relationship rather than avoiding the subject.
Not fully settled:
The regimen actually started, given cost and access considerations to work through with her insurance first.
Flagged as a genuine alternative worth revisiting given her early work shifts, once the immediate-release regimen has had a fair trial.
The addiction specialist’s core point — that the molecule’s history and her actual risk as a monitored, no-misuse-history patient are two different questions — was accepted by both other voices without objection; the group’s only remaining disagreement was practical (dosing burden), not about safety in principle.